sgn-b7h4v
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 12, 2022 (NCT05194072)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Adenoid Cystic · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Cholangiocarcinoma · Phase 1
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Peritoneal Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Payload
- vedotin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068217 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06908928 | Phase 1 | Aug 11, 2025 | Mabwell |
| NCT05194072 | Phase 1 | Jan 12, 2022 | Seattle Genetics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mabwell | For profit | 1 | 1 | 1 | 2025 |
| Seattle Genetics | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1